Phone Number: +16*********
Who is ONCOGENESIS
OncoGenesis addresses the tremendous, unmet clinical need for an easy-to-use and accurate screening of women for cervical cancer. The company offers a comprehensive solution ranging from ...
Read More
- Headquarters: Salt Lake City, Utah, United States
- Date Founded: 2008
- Employees: 1-10
- Revenue: $10 Million to $25 Million
- Active Tech Stack: See technologies
- CEO: Teresa Prego
Industry: Medical Devices
SIC Code: 3841 | NAICS Code: 339112 | Show More
Does something look wrong? Fix it. | View contact records from ONCOGENESIS
OncoGenesis Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding OncoGenesis
Answer: OncoGenesis's headquarters are located at Salt Lake City, Utah, United States
Answer: OncoGenesis's phone number is +16*********
Answer: OncoGenesis's official website is https://oncogenesisdx.com
Answer: OncoGenesis's revenue is $10 Million to $25 Million
Answer: OncoGenesis's SIC: 3841
Answer: OncoGenesis's NAICS: 339112
Answer: OncoGenesis has 1-10 employees
Answer: OncoGenesis is in Medical Devices
Answer: OncoGenesis contact info: Phone number: +16********* Website: https://oncogenesisdx.com
Answer: OncoGenesis addresses the tremendous, unmet clinical need for an easy-to-use and accurate screening of women for cervical cancer. The company offers a comprehensive solution ranging from optimal specimen collection to point-of-care diagnostic testing, setting a new standard of care for diagnosing and treating cervical cancer worldwide. Our goal is to provide a solution that clinically outperforms existing screening technologies in a cost-effective format that can be run anywhere globally, including resource-limited regions of the world where the problem of cervical cancer is a healthcare crisis. To accomplish this, OncoGenesis has developed a useful self-collection device, iPap, that allows women to obtain their cervical specimens in the privacy of their homes. The company is also developing the CerMark multiplex biomarker test that measures the critical cellular changes in a cervical tissue specimen to detect cervical cancer and its progression. The CerMark test will be available first on a laboratory-based system (LAB) and then on our Point-of-Care (POC) device.
Answer:
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Sign in to CIENCE GO Data to uncover contact details
Free credits every month